Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio

Merger Arbeconomics, downside, days

Deal value

—

Per-share offer

—

Premium

—

Days to close

—

Term fee

—

Consideration—

AnnouncedJul 17, 2026

Days outstanding12d

Expected close—

Termination fee—

Reverse term fee—

Go-shop period—

Fiduciary out—

Financing condition—

Debt commitment—

Insider lock-up—

No structured deal economics extracted yet. Re-run the scanner or fall back to the source filing below.

Timelineannounced → close

Announced
Jul 17, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
—
Expected close
—

Vote Mechanicsrecord / mailing / vote

Vote date—

Record date—

Mailing date—

Record → vote—

Threshold—

Min approvalparsed—

Shares outstanding—

Insider lock-up—

Regulatory & ConditionsHSR / EU / CFIUS / MAC

No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.

Closing Conditionsapprovals · vote · financing · lockups

No closing-condition data extracted.

Interloper Riskcompeting bids, activist filers

No competing-bidder, activist, or dissident-proxy signals in the database for this target.

Advisors

No advisor data on record for this deal.

Sources

Press Release

Cellution Biologics signs definitive agreement to acquire SimpliDerm®, expanding its allograft portfolio and entering the U.S. breast reconstruction market

Item id: 5106aafd-049f-4654-9207-6f29ec4b8206 · ingested Jul 17, 2026